The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia

Brain Research Bulletin

Volumn 66, Issue 1, 2005, Pages 43-49

  Erdo, Franciska ^a   Berzsenyi, Pál ^a   Andrási, Ferenc ^a  

^a TEVA PHARMACEUTICALS   (Israel)

Author keywords

AMPA antagonist; Middle cerebral artery occlusion; Photothrombosis; Talampanel; Therapeutic time window

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; GYKI 53405; NEUROPROTECTIVE AGENT; TALAMPANEL; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN RADIATION; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PHOTOCHEMISTRY; PRIORITY JOURNAL; RAT; STAINING; STROKE; THROMBOSIS;

ANIMALS; BENZODIAZEPINES; BRAIN INFARCTION; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; ROSE BENGAL; TETRAZOLIUM SALTS; TIME FACTORS;

EID: 19544365764     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2005.03.012     Document Type: Article

References (53)

1. G. Ábrahám, S. Sólyom, E. Csuzdi, P. Berzsenyi, I. Ling, I. Tarnawa, T. Hámori, I. Pallagi, K. Horváth, F. Andrási, G. Kapus, L.G. Hársing Jr, I. Király, M. Patthy, and G. Horváth New non competitive AMPA antagonists Bioorg. Med. Chem. 8 2000 2127 2143
2. i changes in cultured rat hippocampal neurons Eur. J. Neurosci. 12 2000 2021 2031
3. F. Andrási Talampanel Drugs Fut. 26 2001 754 756
4. F. Andrási, P. Berzsenyi, L. Farkas, J. Korösi, T. Hámori, P. Botka, I. Ling, and T. Láng Omeprazole and talampanel as two examples of retrometabolic drug design Pharmazie 59 2004 365 366
5. J.B. Bederson, L.H. Pitts, S.M. Germano, M.C. Nishimura, R.L. Davis, and H.M. Bartkowski Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats Stroke 17 1986 1304 1308
6. L. Belayev, O.F. Alonso, Y. Liu, A.S. Chappell, W. Zhao, M.D. Ginsberg, and R. Busto Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats J. Neurotrauma 18 2001 1031 1038
7. P. Berzsenyi, F. Andrási, K. Török, K. Horváth, and J.I. Székely Non-competitive AMPA antagonist 2,3-benzodiazepines, contrary to dizocilpine, do not impair memory functions Acta Physiol. Hung. 89 2002 210
8. P. Berzsenyi, H. Szabó, K. Horváth, and F. Andrási Therapeutic potential of AMPA antagonist 2,3-benzodiazepines in neuroprotection and neurodegenerative disorders Fundam. Clin. Pharmacol. 18 S1 2004 46
9. K.K. Borowicz, Z. Kleinrok, and S.J. Czuczwar The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam Naunyn Schmiedebergs Arch. Pharmacol. 361 2000 629 635
10. A.M. Buchan, H. Lesiuk, K.A. Barnes, H. Li, Z.G. Huang, K.E. Smith, and D. Xue AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 24 Suppl. I 1993 I148 I152
11. N. Burnashev, H. Monyer, P.H. Seeburg, and B. Sakmann Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit Neuron 8 1992 189 198
12. H. Carlson, E. Ronne-Engstrom, U. Ungerstedt, and L. Hillered Seizure related elevations of extracellular amino acids in human focal epilepsy Neurosci. Lett. 140 1992 30 32
13. A.S. Chappell, J.W. Sander, M.J. Brodie, D. Chadwick, A. Lledo, D. Zhang, J. Bjerke, G.M. Kiesler, and S. Arroyo A crossover, add-on trial of talampanel in patients with refractory partial seizures Neurology 58 2002 1680 1682
14. ® 1 2004 36 45
15. S.J. Czuczwar, M. Swiader, H. Kuzniar, M. Gasior, and Z. Kleinrok LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs Eur. J. Pharmacol. 359 1998 103 109
16. D. Dewar, P. Yam, and J. McCulloch Drug development for stroke: importance of protecting cerebral white matter Eur. J. Pharmacol. 375 1999 41 50
17. S.D. Donevan, and M.A. Rogawski GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses Neuron 10 1993 51 59
18. J.W. Elting, G.A. Sulter, M. Kaste, K.R. Lees, H.C. Diener, M. Hommel, M. Versavel, A.W. Teelken, and J. De Keyser AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels Stroke 33 2002 2813 2818
19. F. Erdo, T. Trapp, G. Mies, and K.A. Hossmann Immunohistochemical analysis of protein expression after middle cerebral artery occlusion in mice Acta Neuropathol. (Berl.) 107 2004 127 136
20. R. Gill The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia Cerebrovasc. Brain Metab. Rev. 6 1994 225 256
21. M.P. Goldberg Stroke F.W. Marcoux D.W. Choi CNS Neuroprotection 2002 Springer-Verlag Berlin 361 386
22. A.R. Green, T. Odergren, and T. Ashwood Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol. Sci. 24 2003 402 408
23. A.J. Groom, T. Smith, and L. Turski Multiple sclerosis and glutamate Ann. N. Y. Acad. Sci. 993 2003 229 275
24. I. Gyertyán, G. Gigler, and A. Simó The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model Brain Res. Bull. 50 1999 179 186
25. H. Jewell, R. Lucas, H. Schaefer, and T. Mant LY300164 initial experience in healthy subjects Clin. Pharmacol. Ther. 63 1998 188
26. A.D. Kovács, and G. Szabó GYKI 53665, a 2,3-benzodiazepine, non-competitively protects cultured neurons against AMPA toxicity Eur. J. Pharmacol. 331 1997 93 96
27. ® 1 2004 46 70
28. H. Li, and A.M. Buchan Treatment with an AMPA antagonist 12 h following severe normothermic forebrain ischemia prevents CA1 neuronal injury J. Cereb. Blood Flow Metab. 13 1993 933 939
29. D. Lodge, A. Bond, M.J. O'Neill, C.A. Hicks, and M.G. Jones Stereoselective effects of 2, 3-benzodiazepines in vivo: electrophysiology and neuroprotection studies Neuropharmacology 35 1996 1681 1688
30. M. Mackowiak, M.J. O'Neill, C.A. Hicks, D. Bleakman, and P. Skolnick An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study Neuropharmacology 43 2002 1 10
31. E. Matucz, K. Móricz, G. Gigler, A. Simó, J. Barkóczy, G. Lévay, L.G. Hársing Jr, and G. Szénási Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia Brain Res. 1019 1-2 2004 September 3 210 216
32. P.C. May, and P.M. Robison Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures J. Neurochem. 60 1993 1171 1174
33. P.C. May, P.M. Robison, and K.S. Fuson Stereoselective neuroprotection by novel 2,3-benzodiazepine non-competitive AMPA antagonist against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures Neurosci. Lett. 262 1999 219 221
34. B.S. Meldrum Excitatory amino acid receptors and their role in epilepsy and cerebral ischemia Ann. N. Y. Acad. Sci. 757 1995 492 505
35. B. Meldrum, and J. Garthwaite Excitatory amino acid neurotoxicity and neurodegenerative disease Trends Pharmacol. Sci. 11 1990 379 387
36. F.S. Menniti, A.M. Buchan, B.L. Chenard, D.J. Critchett, A.H. Ganong, V. Guanowsky, P.A. Seymour, and W.M. Welch CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo Stroke 34 2003 171 176
37. H. Nagasawa, and K. Kogure Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion Stroke 20 1989 1037 1043
38. J.W. Olney, J. Labruyere, and M.T. Price Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs Science 244 1989 1360 1362
39. J.W. Olney, D.F. Wozniak, V. Jevtovic-Todorovic, N.B. Farber, P. Bittigau, and C. Ikonomidou Drug-induced apoptotic neurodegeneration in the developing brain Brain Pathol. 12 2002 488 498
40. M.J. O'Neill, D. Bleakman, D.M. Zimmerman, and E.S. Nisenbaum AMPA receptor potentiators for the treatment of CNS disorders Curr. Drug Targets CNS Neurol. Disord. 3 2004 181 194
41. D.E. Pellegrini-Giampietro, J.A. Gorter, M.V. Bennett, and R.S. Zukin The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders Trends Neurosci. 20 1997 464 470
42. J.H. Prehn, K. Lippert, and J. Krieglstein Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury? Eur. J. Pharmacol. 292 1995 179 189
43. S.M. Rothman, and J.W. Olney Glutamate and the pathophysiology of hypoxic-ischemic brain damage Ann. Neurol. 19 1986 105 111
44. M.J. Sheardown, E.O. Nielsen, A.J. Hansen, P. Jacobsen, and T. Honore 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia Science 247 1990 571 574
45. M. Shimizu-Sasamata, S. Kawasaki-Yatsugi, M. Okada, S. Sakamoto, S. Yatsugi, J. Togami, K. Hatanaka, J. Ohmori, K. Koshiya, S. Usuda, and K. Murase YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist J. Pharmacol. Exp. Ther. 276 1996 84 92
46. S.E. Smith, and B.S. Meldrum Cerebroprotective effect of a non-N-methyl-d-aspartate antagonist, GYKI 52466, after focal ischemia in the rat Stroke 23 1992 861 864
47. T. Smith, A. Groom, B. Zhu, and L. Turski Autoimmune encephalomyelitis ameliorated by AMPA antagonists Nat. Med. 6 2000 62 66
48. S. Sólyom, and I. Tarnawa Non-competitive AMPA antagonists of 2,3-benzodiazepine type Curr. Pharm. Des. 8 2002 913 939
49. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development, Stroke 30 (1999) 2751-2758.
50. I. Tarnawa, and E.S. Vizi 2,3-Benzodiazepine AMPA antagonists Restor. Neurol. Neurosci. 13 1998 41 57
51. L. Turski, A. Huth, M. Sheardown, F. McDonald, R. Neuhaus, H.H. Schneider, U. Dirnagl, F. Wiegand, P. Jacobsen, and E. Ottow ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma Proc. Natl. Acad. Sci. U.S.A. 95 1998 10960 10965
52. I. Világi, J. Takács, A. Gulyás-Kovács, I. Banczerowski-Pelyhe, and I. Tarnawa Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats Brain Res. Bull. 59 2002 35 40
53. B.D. Watson, W.D. Dietrich, R. Busto, M.S. Wachtel, and M.D. Ginsberg Induction of reproducible brain infarction by photochemically initiated thrombosis Ann. Neurol. 17 1985 497 504